Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660

Bray F, Laversanne M, Weiderpass E, et al., 2021, The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(6): 3029–30. https://doi.org/10.1002/cncr.33587 

Xia C, Dong X, Li H, et al., 2022, Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin Med J (Engl), 135(5): 584–590. https://doi.org/10.1097/CM9.0000000000002108 

Avella Patino DM, Radhakrishnan V, Suvilesh KN, et al., 2022, Epigenetic regulation of cancer immune cells. Semin Cancer Biol, 83: 377–383. https://doi.org/10.1016/j.semcancer.2021.06.022 

Chen C, Man N, Liu F, et al., 2022, Epigenetic and transcriptional regulation of innate immunity in cancer. Cancer Res, 82(11): 2047–2056. https://doi.org/10.1158/0008-5472.CAN-21-3503

Berdasco M, Esteller M, 2010, Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev Cell, 19(5): 698–711. https://doi.org/10.1016/j.devcel.2010.10.005

Torry DS, Cooper GM, 1991, Proto-oncogenes in development and cancer. Am J Reprod Immunol, 25(3): 129–132. https://doi.org/10.1111/j.1600-0897.1991.tb01080.x 

Spandidos DA, Anderson ML, 1989, Oncogenes and onco-suppressor genes: Their involvement in cancer. J Pathol, 157(1): 1–10. https://doi.org/10.1002/path.1711570102

Sharma S, Kelly TK, Jones PA, 2010, Epigenetics in cancer. Carcinogenesis, 31(1): 27–36. https://doi.org/10.1093/carcin/bgp220 

Baeriswyl V, Christofori G, 2009, The angiogenic switch in carcinogenesis. Semin Cancer Biol, 19(5): 329–337. https://doi.org/10.1016/j.semcancer.2009.05.003

Bergers G, Benjamin LE, 2003, Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3(6): 401–410. https://doi.org/10.1038/nrc1093

Robert J, 2013, Biology of cancer metastasis. Bull Cancer, 100(4): 333–342. https://doi.org/10.1684/bdc.2013.1724

Suhail Y, Cain MP, Vanaja K, et al., 2019, Systems biology of cancer metastasis. Cell Syst, 9(2): 109–127. https://doi.org/10.1016/j.cels.2019.07.003

Fidler IJ, 2003, The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev Cancer, 3(6): 453–458. https://doi.org/10.1038/nrc1098 

Lambert AW, Pattabiraman DR, Weinberg RA, 2017, Emerging biological principles of metastasis. Cell, 168(4): 670–691. https://doi.org/10.1016/j.cell.2016.11.037 

Massague J, Obenauf AC, 2016, Metastatic colonization by circulating tumour cells. Nature, 529(7586): 298–306. https://doi.org/10.1038/nature17038

Li Y, Li F, Jiang F, et al., 2016, A mini-review for cancer immunotherapy: Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci, 17(7): 1151. https://doi.org/10.3390/ijms17071151 

Zhang H, Zhou D, Gu J, et al., 2021, Targeting the mu-opioid receptor for cancer treatment. Curr Oncol Rep, 23(10): 111. https://doi.org/10.1007/s11912-021-01107-w

Ramirez MF, Gorur A, Cata JP, 2021, Opioids and cancer prognosis: A summary of the clinical evidence. Neurosci Lett, 746: 135661. https://doi.org/10.1016/j.neulet.2021.135661 

Trescot AM, Datta S, Lee M, et al., 2008, Opioid pharmacology. Pain Physician, 11(2 Suppl): S133–S153.

Spetea M, Schmidhammer H, 2020, Opioids and their receptors: Present and emerging concepts in opioid drug discovery. Molecules, 25(23): 5658. https://doi.org/10.3390/molecules25235658 

Ballantyne JC, 2006, Opioids for chronic nonterminal pain. South Med J, 99(11): 1245–1255. https://doi.org/10.1097/01.smj.0000223946.19256.17

Hughes J, Smith TW, Kosterlitz HW, et al., 1975, Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature, 258(5536): 577–580. https://doi.org/10.1038/258577a0

Rosenblum A, Marsch LA, Joseph H, et al., 2008, Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol, 16: 405–416. https://doi.org/10.1037/a0013628

Dickenson AH, 1994, The localization and mechanisms of action of opioids. Eksp Klin Farmakol, 57(6): 3–12. 

Bovill JG, 1997, Mechanisms of actions of opioids and non-steroidal anti-inflammatory drugs. Eur J Anaesthesiol Suppl, 15: 9–15. https://doi.org/10.1097/00003643-199705001-00003 

Nelson AD, Camilleri M, 2016, Opioid-induced constipation: Advances and clinical guidance. Ther Adv Chronic Dis, 7(2): 121–134. https://doi.org/10.1177/2040622315627801

Pattinson KT, 2008, Opioids and the control of respiration. Br J Anaesth, 100(6): 747–758. https://doi.org/10.1093/bja/aen094 

Mao J, 2002, Opioid-induced abnormal pain sensitivity: Implications in clinical opioid therapy. Pain, 100: 213–217. https://doi.org/10.1016/S0304-3959(02)00422-0 

DeLeo JA, Tanga FY, Tawfik VL, 2004, Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist, 10(1): 40–52. https://doi.org/10.1177/1073858403259950

Stein C, Zollner C, 2009, Opioids and sensory nerves. Handb Exp Pharmacol, 194: 495–518. https://doi.org/10.1007/978-3-540-79090-7_14

Kosten TR, 1990, Neurobiology of abused drugs. Opioids and stimulants. J Nerv Ment Dis, 178(4): 217–227. https://doi.org/10.1097/00005053-199004000-00001

Colasanti A, Rabiner EA, Lingford-Hughes A, et al., 2011, Opioids and anxiety. J Psychopharmacol, 25: 1415–1433. 

Waldhoer M, Bartlett SE, Whistler JL, 2004, Opioid receptors. Annu Rev Biochem, 73: 953–990. https://doi.org/10.1146/annurev.biochem.73.011303.073940 

Zaki PA, Bilsky EJ, Vanderah TW, et al., 1996, Opioid receptor types and subtypes: The delta receptor as a model. Annu Rev Pharmacol Toxicol, 36: 379–401. https://doi.org/10.1146/annurev.pa.36.040196.002115

Kieffer BL, Evans CJ, 2009, Opioid receptors: From binding sites to visible molecules in vivo. Neuropharmacology, 56 Suppl 1: 205–212. https://doi.org/10.1016/j.neuropharm.2008.07.033 

Mansour A, Fox CA, Akil H, et al., 1995, Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications. Trends Neurosci, 18(1): 22–29. https://doi.org/10.1016/0166-2236(95)93946-u

Xia Y, Haddad GG, 1991, Ontogeny and distribution of opioid receptors in the rat brainstem. Brain Res, 549(2): 181–193. https://doi.org/10.1016/0006-8993(91)90457-7 

Wittert G, Hope P, Pyle D, 1996, Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun, 218(3): 877–881. https://doi.org/10.1006/bbrc.1996.0156

Peng J, Sarkar S, Chang SL, 2012, Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend, 124(3): 223–228. https://doi.org/10.1016/j.drugalcdep.2012.01.013

Mollereau C, Parmentier M, Mailleux P, et al., 1994, ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett, 341(1): 33–38. https://doi.org/10.1016/0014-5793(94)80235-1 

Meunier JC, Mollereau C, Toll L, et al., 1995, Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 377(6549): 532–535. https://doi.org/10.1038/377532a0 

Akil H, Watson SJ, Young E, et al., 1984, Endogenous opioids: Biology and function. Annu Rev Neurosci, 7: 223–255. https://doi.org/10.1146/annurev.ne.07.030184.001255 

Kieffer BL, 1995, Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides. Cell Mol Neurobiol, 15(6): 615–635. https://doi.org/10.1007/BF02071128

Colvin LA, Bull FB, Hales TG, 2019, Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet, 393(10180): 1558–1568. https://doi.org/10.1016/S0140-6736(19)30430-1

Streicher JM, Bilsky EJ, 2018, Peripherally acting mu-opioid receptor antagonists for the treatment of opioid-related side effects: Mechanism of action and clinical implications. J Pharm Pract, 31(6): 658–669. https://doi.org/10.1177/0897190017732263

Trang T, Al-Hasani R, Salvemini D, et al., 2015, Pain and poppies: The good, the bad, and the ugly of opioid analgesics. J Neurosci, 35(41): 13879–13888. https://doi.org/10.1523/JNEUROSCI.2711-15.2015

Eisenstein TK, 2019, The role of opioid receptors in immune system function. Front Immunol, 10: 2904. https://doi.org/10.3389/fimmu.2019.02904 

Giugliano D, Torella R, Lefèbvre PJ, et al., 1988, Opioid peptides and metabolic regulation. Diabetologia, 31(1): 3–15. https://doi.org/10.1007/BF00279126 

Meng J, Yu H, Ma J, et al., 2013, Morphine induces bacterial translocation in mice by compromising intestinal barrier function in a TLR-dependent manner. PLoS One, 89(1): e54040. https://doi.org/10.1371/journal.pone.0054040

Tuerxun H, Cui J, 2019, The dual effect of morphine on tumor development. Clin Transl Oncol, 21(6): 695–701. https://doi.org/10.1007/s12094-018-1974-5

Gupta K, Chen C, Lutty GA, et al., 2019, Morphine promotes neovascularizing retinopathy in sickle transgeneic mice. Blood Adv, 3(7): 1073–1083. https://doi.org/10.1182/bloodadvances.2018026898

Lu H, Zhang H, Weng ML, et al., 2021, Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J Cell Physiol, 236(6): 4445–4454. https://doi.org/10.1002/jcp.30161

Zhang H, Sun M, Zhou D, et al., 2020, Increased mu-opioid receptor expression is associated with reduced disease-free and overall survival in laryngeal squamous cell carcinoma. Br J Anaesth, 125(5): 722–729. https://doi.org/10.1016/j.bja.2020.07.051

Zhang JJ, Song CG, Dai JM, et al., 2021, Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway. Am J Transl Res, 13(5): 3967–3986. 

Janku F, Johnson LK, Karp DD, et al., 2016, Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol, 27(11): 2032–2038. https://doi.org/10.1093/annonc/mdw317

Kieffer BL, 1999, Opioids: First lessons from knockout mice. Trends Pharmacol Sci, 20(1): 19–26. https://doi.org10.1016/s0165-6147(98)01279-6

Corder G, Castro DC, Bruchas MR, et al., 2018, Endogenous and exogenous opioids in pain. Annu Rev Neurosci, 41: 453–473. https://doi.org/10.1146/annurev-neuro-080317-061522 

Erbs E, Faget L, Scherrer G, et al., 2015, A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct, 220(2): 677–702. https://doi.org/10.1007/s00429-014-0717-9

Fields H, 2004, State-dependent opioid control of pain. Nat Rev Neurosci, 5(7): 565–575. https://doi.org/10.1038/nrn1431

Scherrer G, Imamachi N, Cao YQ, et al., 2009, Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell, 137(6): 1148–1159. https://doi.org/10.1016/j.cell.2009.04.019

Pasternak GW, Pan YX, 2013, Mu opioids and their receptors: Evolution of a concept. Pharmacol Rev, 65(4): 1257–1317. https://doi.org/10.1124/pr.112.007138 

Stein C, 2016, Opioid receptors. Annu Rev Med, 67: 433–451. https://doi.org/10.1146/annurev-med-062613-093100 

Spike RC, Puskár Z, Sakamoto H, et al., 2002, MOR-1- immunoreactive neurons in the dorsal horn of the rat spinal cord: Evidence for nonsynaptic innervation by substance P-containing primary afferents and for selective activation by noxious thermal stimuli. Eur J Neurosci, 15(8): 1306–1316. https://doi.org/10.1046/j.1460-9568.2002.01969.x 

Wang D, Tawfik VL, Corder G, et al., 2018, Functional divergence of Delta and Mu opioid receptor organization in CNS pain circuits. Neuron, 98(1): 90–108.e5. https://doi.org/10.1016/j.neuron.2018.03.002

Gardon O, Faget L, Chu Sin Chung P, et al., 2014, Expression of mu opioid receptor in dorsal diencephalic conduction system: New insights for the medial habenula. Neuroscience, 277: 595–609. https://doi.org/10.1016/j.neuroscience.2014.07.053

Wager TD, Scott DJ, Zubieta JK, 2007, Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci U S A, 104(26): 11056–11061. https://doi.org/10.1073/pnas.0702413104

Zubieta JK, Bueller JA, Jackson LR, et al., 2005, Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci, 25(34): 7754–7562. https://doi.org/10.1523/JNEUROSCI.0439-05.2005

Cheng S, Guo M, Liu Z, et al., 2019, Morphine promotes the angiogenesis of postoperative recurrent tumors and metastasis of dormant breast cancer cells. Pharmacology, 104(5–6): 276–286. https://doi.org/10.1159/000502107

Song Z, Huang S, Yu H, et al., 2017, Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem, 133: 329–339. https://doi.org/10.1016/j.ejmech.2017.03.083

Ma M, Wang X, Liu N, et al., 2020, Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway. Int Immunopharmacol, 83: 106388. https://doi.org/10.1016/j.intimp.2020.106388

Cata JP, Uhelski ML, Gorur A, et al., 2002, The μ-opioid receptor in cancer and its role in perineural invasion: A short review and new evidence. Adv Biol (Weinh), 6(9): e2200020. https://doi.org/10.1002/adbi.202200020

Scopsi L, Balslev E, Brünner N, et al., 1989, Immunoreactive opioid peptides in human breast cancer. Am J Pathol, 134(2): 473–479. 

Bortsov AV, Millikan RC, Belfer I, et al., 2012, μ-Opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology, 116(4): 896–902. https://doi.org/10.1097/ALN.0b013e31824b96a1

Cao W, Lee H, Wu W, et al., 2020, Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nat Commun, 11(1): 3675. https://doi.org/10.1038/s41467-020-17227-z 

Gao P, Mu M, Chen Y, et al., 2021, Corrigendum to “Yes-associated protein upregulates filopodia formation to promote alveolar epithelial-cell phagocytosis” Immunol. Lett. 225 (2020) 44-49]. Immunol Lett, 239: 113–115. https://doi.org/10.1016/j.imlet.2021.03.005

Lu Z, Xu J, Xu M, et al., 2018, Truncated μ-opioid receptors with 6 transmembrane domains are essential for opioid analgesia. Anesth Analg, 126(3): 1050–1057. https://doi.org/10.1213/ANE.0000000000002538 

Zhang H, 2022, Cancer pain management-new therapies. Curr Oncol Rep, 24(2): 223–226. https://doi.org/10.1007/s11912-021-01166-z

Santoni A, Santoni M, Arcuri E, 2022, Chronic cancer pain: Opioids within tumor microenvironment affect neuroinflammation, tumor and pain evolution. Cancers (Basel), 14(9): 2253. https://doi.org/10.3390/cancers14092253

Scroope CA, Singleton Z, Hollmann MW, et al., 2021, Opioid receptor-mediated and non-opioid receptor-mediated roles of opioids in tumour growth and metastasis. Front Oncol, 11: 792290. https://doi.org/10.3389/fonc.2021.792290

Heaney A, Buggy DJ, 2012, Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth, 109 Suppl 1: i17–i28. https://doi.org/10.1093/bja/aes421

Li Y, Li G, Tao T, et al., 2019, The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Lett, 453: 1–9. https://doi.org/10.1016/j.canlet.2019.03.038 

Rogers JB, Higa GM, 2022, Spoken and unspoken matters regarding the use of opioids in cancer. J Pain Res, 15: 909–924. https://doi.org/10.2147/JPR.S349107

Zylla D, Gourley BL, Vang D, et al., 2013, Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer, 119(23): 4103–4110. https://doi.org/10.1002/cncr.28345

Lennon FE, Mirzapoiazova T, Mambetsariev B, et al., 2012, Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology, 116(4): 857–867. https://doi.org/10.1097/ALN.0b013e31824babe2 

Liu X, Yang J, Yang C, et al., 2021, Morphine promotes the malignant biological behavior of non-small cell lung cancer cells through the MOR/Src/mTOR pathway. Cancer Cell Int, 21(1): 622. https://doi.org/10.1186/s12935-021-02334-8 

Lu J, Liu Z, Zhao L, et al., 2013, In vivo and in vitro inhibition of human liver cancer progress by downregulation of the μ-opioid receptor and relevant mechanisms. Oncol Rep, 30(4): 1731–1738. https://doi.org/10.3892/or.2013.2640

Belltall A, Mazzinari G, Garrido-Cano I, et al., 2022, Opioid receptor expression in colorectal cancer: A nested matched case-control study. Front Oncol, 12: 801714. https://doi.org/10.3389/fonc.2022.801714

Haque MR, Barlass U, Armstrong A, et al., 2022, Novel role of the Mu-opioid receptor in pancreatic cancer: Potential link between opioid use and cancer progression. Mol Cell Biochem, 477(5): 1339–1345. https://doi.org/10.1007/s11010-022-04377-5 

Li T, Kang G, Wang T, et al., 2018, Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett, 16(1): 687–702. https://doi.org/10.3892/ol.2018.8733

Harry JA, Ormiston ML, 2021, Novel pathways for targeting tumor angiogenesis in metastatic breast cancer. Front Oncol, 11: 772305. https://doi.org/10.3389/fonc.2021.772305

Koodie L, Ramakrishnan S, Roy S, 2010, Morphine suppresses tumor angiogenesis through a HIF-1alpha/ p38MAPK pathway. Am J Pathol, 177(2): 984–997. https://doi.org/10.2353/ajpath.2010.090621 

Singleton PA, Mirzapoiazova T, Hasina R, et al., 2014, Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth, 113 Suppl 1: i103–i108. https://doi.org/10.1093/bja/aeu165

Bimonte S, Barbieri A, Rea D, et al., 2015, Morphine promotes tumor angiogenesis and increases breast cancer progression. Biomed Res Int, 2015: 161508. https://doi.org/10.1155/2015/161508

Murohara T, Asahara T, 2002, Nitric oxide and angiogenesis in cardiovascular disease. Antioxid Redox Signal, 4(5): 825–831. https://doi.org/10.1089/152308602760598981

Dimmeler S, Zeiher AM, 2000, Endothelial cell apoptosis in angiogenesis and vessel regression. Circ Res, 87(6): 434–439.

Hsiao PN, Chang MC, Cheng WF, et al., 2009, Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology, 256(1–2): 83–91. https://doi.org/10.1016/j.tox.2008.11.015

Ziche M, Morbidelli L, 2000, Nitric oxide and angiogenesis. J Neurooncol, 50(1–2): 139–148. https://doi.org/10.1023/a:1006431309841 

Kenny PA, Lee GY, Bissell MJ, Targeting the tumor microenvironment. Front Biosci, 12: 3468–3474. https://doi.org/10.2741/2327

Sung SY, Hsieh CL, Wu D, et al., 2007, Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer, 31(2): 36–100. https://doi.org10.1016/j.currproblcancer.2006.12.002

Fang H, Declerck YA, 2013, Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res, 73(16): 4965–4977. https://doi.org/10.1158/0008-5472.CAN-13-0661

Liang X, Liu R, Chen C, et al., 2016, Opioid system modulates the immune function: A review. Transl Perioper Pain Med, 1(1): 5–13.

Koodie L, Yuan H, Pumper JA, et al., 2014, Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol, 184(4): 1073–1084. https://doi.org/10.1016/j.ajpath.2013.12.019

Jiang Y, Li T, Qian Y, et al., 2022, Morphine in combination with ketamine improves cervical cancer pain and suppresses immune function via the JAK3/STAT5 pathway. Pain Res Manag, 2022: 9364365. https://doi.org/10.1155/2022/9364365

Zielińska M, Szymaszkiewicz A, Jacenik D, et al., 2020, Cyclic derivative of morphiceptin Dmt-cyclo-(D-Lys-Phe- D-Pro-Asp)-NH2(P-317), a mixed agonist of MOP and KOP opioid receptors, exerts anti-inflammatory and anti-tumor activity in colitis and colitis-associated colorectal cancer in mice. Eur J Pharmacol, 885: 173463. https://doi.org/10.1016/j.ejphar.2020.173463

Boehncke S, Hardt K, Schadendorf D, et al., 2011, Endogenous μ-opioid peptides modulate immune response towards malignant melanoma. Exp Dermatol, 20(1): 24–28. https://doi.org/10.1111/j.1600-0625.2010.01158.x 

Coluzzi F, Rullo L, Scerpa MS, et al., 2022, Current and future therapeutic options in pain management: Multi-mechanistic opioids involving both MOR and NOP receptor activation. CNS Drugs, 36(6): 617–632. https://doi.org/10.1007/s40263-022-00924-2

Gorur A, Patiño M, Shi T, et al., 2021, Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. J Cell Physiol, 236(11): 7698–7710. https://doi.org/10.1002/jcp.30421

Singleton PA, Moss J, 2010, Effect of perioperative opioids on cancer recurrence: A hypothesis. Future Oncol, 6(8): 1237–1242. https://doi.org/10.2217/fon.10.99

da Silva JL, Dos Santos AL, Nunes NC, de Moraes Lino da Silva F, et al., 2019, Cancer immunotherapy: The art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol, 84(4): 227–240. https://doi.org/10.1007/s00280-019-03894-3 

Esfahani K, Roudaia L, Buhlaiga N, et al., 2020, A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol, 27: S87–S97. https://doi.org/10.3747/co.27.5223 

Emens LA, 2018, Breast cancer immunotherapy: Facts and hopes. Clin Cancer Res, 24(3): 511–520. https://doi.org/10.1158/1078-0432.CCR-16-3001

Chen G, Kim YH, Li H, et al., 2017, PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci, 20(7): 917–926. https://doi.org/10.1038/nn.4571

McLaughlin PJ, Verderame MF, Hankins JL, et al., 2007, Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med, 19(3): 421–428.

Zagon IS, McLaughlin PJ, 2014, Opioid growth factor and the treatment of human pancreatic cancer: A review. World J Gastroenterol, 20(9): 2218–2223. https://doi.org/10.3748/wjg.v20.i9.2218 

Kim JY, Ahn HJ, Kim JK, et al., 2016, Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: An in vitro and human lung tissue study. Anesth Analg, 123(3): 1429–1436.

Ma Y, Ren Z, Ma S, et al., 2017, Morphine enhances renal cell carcinoma aggressiveness through promotes survivin level. Ren Fail, 39(1): 258–64.

Belltall A, Zúñiga-Trejos S, Garrido-Cano I, et al., 2022, Solid tumor opioid receptor expression and oncologic outcomes: Analysis of the cancer genome atlas and genotype tissue expression project. Front Oncol, 12: 801411. https://doi.org/10.3389/fonc.2022.801411 

Zhang H, Qu M, Gorur A, et al., 2021, Association of Mu-opioid receptor(MOR) expression and opioids requirement with survival in patients with stage I-III pancreatic ductal adenocarcinoma. Front Oncol, 11: 686877. https://doi.org/10.3389/fonc.2021.686877 

Díaz-Cambronero O, Mazzinari G, Giner F, et al., 2020, Mu opioid receptor 1 (MOR-1) expression in colorectal cancer and oncological long-term outcomes: A five-year retrospective longitudinal cohort study. Cancers (Basel), 12(1): 134. https://doi.org/10.3390/cancers12010134

Wang H, Luo J, Chen X, et al., 2022, Clinical observation of the effects of oral opioid on inflammatory cytokines and gut microbiota in patients with moderate to severe cancer pain: A retrospective cohort study. Pain Ther, 11(2): 667–681. https://doi.org/10.1007/s40122-022-00386-w

Edwards KA, Havelin JJ, Mcintosh MI, et al., 2018, A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain. J Pain, 19(6): 612–625. https://doi.org/10.1016/j.jpain.2018.01.002

Huang HM, He XH, Huang XY, et al., 2022, Down-regulation of kappa opioid receptor promotes ESCC proliferation, invasion and metastasis via the PDK1-AKT signaling pathway. Cell Commun Signal, 20(1): 35. https://doi.org/10.1186/s12964-022-00833-3

Zhang YF, Xu QX, Liao LD, et al., 2013, κ-Opioid receptor in the nucleus is a novel prognostic factor of esophageal squamous cell carcinoma. Hum Pathol, 44(9): 1756–1765. https://doi.org/10.1016/j.humpath.2012.11.025

Xie N, Matigian N, Vithanage T, et al., 2018, Effect of perioperative opioids on cancer-relevant circulating parameters: Mu opioid receptor and toll-like receptor 4 activation potential, and proteolytic profile. Clin Cancer Res, 24(10): 2319–2327. https://doi.org/10.1158/1078-0432.CCR-18-0172

Fu J, Xu M, Xu L, et al., 2021, Sulforaphane alleviates hyperalgesia and enhances analgesic potency of morphine in rats with cancer-induced bone pain. Eur J Pharmacol, 909: 174412. https://doi.org/10.1016/j.ejphar.2021.174412

Maher DP, Wong W, White PF, et al., 2014, Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: A retrospective analysis. Br J Anaesth, 113 Suppl 1: i88–i94. https://doi.org/10.1093/bja/aeu192

Szczepaniak A, Fichna J, Zielińska M, 2022, Opioids in cancer development, progression and metastasis: Focus on colorectal cancer. Curr Treat Options Oncol, 21(1): 6. https://doi.org/10.1007/s11864-019-0699-1

Cadet P, Rasmussen M, Zhu W, et al., 2004, Endogenous morphinergic signaling and tumor growth. Front Biosci, 9: 3176–3186. https://doi.org/10.2741/1471

Tan M, Wang H, Gao C, et al., Agonists specific for kappa-opioid receptor induces apoptosis of HCC cells through enhanced endoplasmic reticulum stress. Front Oncol, 12: 844214. https://doi.org/10.3389/fonc.2022.844214 

Lin ZZ, Bo N, Fan YC, et al., 2022, Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via Μu-opioid receptor. J Pharm Pharmacol, 74(1): 139–146. https://doi.org/10.1093/jpp/rgab104